FibroGen To Report First Quarter 2020 Financial Results
April 24 2020 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020
financial results on Thursday, May 7, 2020. FibroGen will also
conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m.
PT) with the investment community to further detail the company's
corporate and financial performance.
Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the
conference call via the FibroGen website at
https://fibrogen.gcs-web.com/events-and-presentations/events. It is
recommended that listeners access the website 15 minutes prior to
the start of the call to download and install any necessary audio
software.
Dial-In InformationLive
(U.S./Canada): (877) 658-9081Live (International): (602)
563-8732Confirmation number: 9946439
A replay of the webcast will be available shortly
after the call for a period of two weeks. To access the replay,
please dial (855) 859-2056 (domestic) or (404) 537-3406
(international), and use passcode 9946439.
About FibroGen FibroGen, Inc.,
headquartered in San Francisco, California, with subsidiary offices
in Beijing and Shanghai, People’s Republic of China, is a
biopharmaceutical company discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology,
and clinical development to advance innovative medicines for the
treatment of anemia, fibrotic disease, and cancer. Roxadustat, the
company’s most advanced product, an oral small molecule inhibitor
of HIF prolyl hydroxylase activity, is approved by the National
Medical Products Administration in China for CKD patients on
dialysis and not on dialysis and by the Ministry of Health, Labour
and Welfare in Japan for CKD patients on dialysis. The NDA filing
for roxadustat for the treatment of CKD anemia was accepted by the
U.S. Food and Drug Administration in February 2020. Our partner
Astellas expects the Marketing Authorization Application filing for
roxadustat for the treatment of anemia in both dialysis- and
non-dialysis-dependent patients with CKD to the European Medicines
Agency in the second quarter of 2020. Roxadustat is in Phase 3
clinical development in the U.S. and Europe and in Phase 2/3
development in China for anemia associated with myelodysplastic
syndromes (MDS), and in a Phase 2 U.S. trial for treatment of
chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in Phase 3 clinical development for the
treatment of idiopathic pulmonary fibrosis (IPF) and locally
advanced unresectable pancreatic cancer, and is currently in a
Phase 2 trial for Duchenne muscular dystrophy (DMD). For more
information, please visit www.fibrogen.com.
Contact: FibroGen, Inc.
Media Inquiries: Sara Iacovino 1.703.474.4452
sara.iacovino@gcihealth.com
Investors: Michael Tung, M.D.Corporate Strategy /
Investor Relations1.415.978.1434mtung@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024